Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL FE 1/20 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche),Management of menstrual disorders (off-label)
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in pediatric patients. Not indicated for use before menarche.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction),Hepatic neoplasia (benign and malignant),Gallbladder disease,Hypertension,Carbohydrate and lipid metabolic effects,Headache,Bleeding irregularities,Depression,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs,Use in pregnancy (discontinue if pregnancy occurs)
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis, thromboembolic disorders, or history of these conditions,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions. Grapefruit juice may theoretically increase estrogen levels but clinical significance is minimal; routine avoidance not required. Iron tablets (ferrous fumarate) may cause gastrointestinal upset; taking with food may reduce nausea. Avoid high-dose vitamin C supplements as they may increase estrogen absorption, but normal dietary intake is safe.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses).
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and norethindrone (the active components) are excreted into breast milk. The M/P ratio is approximately 0.1-0.3 for ethinyl estradiol and 0.5-1.0 for norethindrone. Use is generally not recommended during breastfeeding as it may reduce milk production and quality. If used, monitor infant for jaundice and growth.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated; no dose adjustment is indicated as the drug should be discontinued immediately upon pregnancy detection.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Junel Fe 1/20 is a combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone 1 mg. It is a low-dose pill; efficacy may be slightly lower than higher-dose pills. The iron supplement (ferrous fumarate) in the placebo pills is not intended for contraception; patients should not skip active pills. Missed pills increase risk of ovulation; if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception for 7 days. Counsel on signs of venous thromboembolism (VTE): sudden leg pain, chest pain, shortness of breath. Consider alternatives in migraine with aura, uncontrolled hypertension, or smokers over 35. Drug interactions include rifampin, certain anticonvulsants (phenytoin, carbamazepine), and St. John's Wort which may reduce efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time; the last 7 pills in each pack are iron tablets and do not provide contraception.,If you miss an active pill, take it as soon as you remember. If you miss two or more active pills, use a backup contraceptive method (e.g., condoms) for the next 7 days.,Vomiting or severe diarrhea within 4 hours of taking an active pill may reduce effectiveness; treat as a missed pill and consult your clinician.,Notify your clinician if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,Avoid smoking while on this medication, especially if over 35 years old, as it increases the risk of serious cardiovascular events.,Inform your clinician of all medications you take, including over-the-counter products and herbal supplements.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL FE 1/20 vs ALYACEN 7/7/7, answered by our medical review team.
JUNEL FE 1/20 is a Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL FE 1/20 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL FE 1/20 is: One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL FE 1/20 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL FE 1/20 is classified as Category C. Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defe. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.